Comparison of demographic characteristics of AD, LBD, HD patients and non-demented controls from the Mayo Clinic Study of Aging, the Pacific Udall Center, the Alzheimer’s Disease Research Center, and the Adult Changes in Thought Study, the NIH NeuroBioBank, and the New York brain bank.

Comparison of demographic characteristics of AD, LBD, HD patients and non-demented controls from the Mayo Clinic Study of Aging, the Pacific Udall Center, the Alzheimer’s Disease Research Center, and the Adult Changes in Thought Study, the NIH NeuroBioBank, and the New York brain bank.</p

Cp-values for housekeeping genes.

(A) Cp-values for PPIA are significantly higher in cognitively impaired individuals (CI) compared to cognitively normal controls (CN). (B) Cp-values for RPL13 do not differ between CI and CN groups.</p

Caspase-2S relative mRNA expression levels in neurological disease.

(A) Caspase-2S mRNA expression levels trend lower in AD but not MCI compared to CN controls. Caspase-2S mRNA do not differ in LBD (B) or HD (C) compared to controls.</p

RT-qPCR crossing points correlate with RNA integrity numbers.

Crossing point (Cp) values for housekeeping genes RPL13 (A) and PPIA (B), and caspase-2L (C) are significantly correlated with RIN number. RPL13 (D), PPIA (E) and caspase-2L (F) Cp-values after a cutoff of RIN ≥ 3.9 no longer show a significant negative correlation.</p

βIII-tubulin relative mRNA expression levels in neurological disease.

βIII-tubulin mRNA levels do not differ in AD and MCI (A), LBD (B) or HD (C) compared to controls.</p

SNAP-25 relative mRNA expression levels in neurological disease.

(A) SNAP-25 mRNA levels are significantly lower in AD and trend lower in MCI, LBD (B), and HD (C).</p

Revised patient demographics of samples with RIN > = 3.9.

(DOCX)</p

IDT PrimeTime qPCR probe assays used in this study.

(DOCX)</p

Relative mRNA expression levels for caspase-2L in neurological disease.

Caspase-2L Cp-values (A), RPL13 Cp-values (B), and relative caspase-2L mRNA expression levels (C) do not differ in MCI and AD samples compared to controls. Caspase-2L Cp-values (D), RPL13 Cp-values (E), and relative caspase-2L mRNA expression levels (F) do not differ in LBD compared to non-demented PD controls. Caspase-2L Cp-values (G), RPL13 Cp-values (H), and relative caspase-2L mRNA expression levels (I) do not differ in HD compared to controls.</p

S1 Data -

(XLSX)</p